Clinical Trial Update: Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II open-label trial of combining the STAT3 inhibitor TTI-101 with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TTI-101

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN